RxDoctor Payments Data

Nathan Jones, MD

Hospice and Palliative Medicine · Newnan, GANPI 1962852632

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 27.0% of the total. Reporting peaked in 2023 at $209 and has fallen 92.9% since, to $15 in 2025.

$651in general payments, 2019–2025

Across 43 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$176
  • Novartis$84
  • Lilly USA, LLC$58
  • GSK$48
  • Sun Pharmaceutical Industries Inc.$44
  • Boehringer Ingelheim$30
  • plus $212 from 11 others

What the payments were for

  • Food & beverage$63698%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$651 in reported general payments places this provider in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.

See all hospice and palliative medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$9,940
Medicare patients
40
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$55,129
EliquisApixaban52$40,350
JardianceEmpagliflozin41$38,315
RybelsusSemaglutide14$28,025
XareltoRivaroxaban27$23,243
LinzessLinaclotide11$10,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,311
Spiriva RespimatTiotropium Bromide15$7,781
Dexlansoprazole DrDexlansoprazole17$3,535
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,485
Levothyroxine Sodium178$1,867
Tramadol Hcl69$1,602
Albuterol Sulfate HfaAlbuterol Sulfate55$1,510
SynthroidLevothyroxine Sodium20$1,425
Atorvastatin Calcium229$1,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$176$83,15355 claims
Boehringer IngelheimJardiance, Spiriva Respimat$30$46,09656 claims
PfizerEliquis$28$40,35052 claims
AbbVieLinzess, Synthroid$26$11,91431 claims
GSKTrelegy Ellipta$48$10,31114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.

Other hospice and palliative medicine in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →